Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
Treatment of Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia by Chimeric Antigen Receptor (CAR)-Modified T Cells
Sponsor: Affiliated Hospital to Academy of Military Medical Sciences
A PHASE1 clinical study on Acute Lymphoblastic Leukemia, this trial is ongoing. The trial is conducted by Affiliated Hospital to Academy of Military Medical Sciences and has accumulated 8 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Mar 2023 — Jul 2024 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Mar 2021 — Mar 2023 [monthly]
Recruiting PHASE1
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE1
Status: Unknown Status → Recruiting
▶ Show 3 earlier versions
-
Sep 2018 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Affiliated Hospital to Academy of Military Medical Sciences
For direct contact, visit the study record on ClinicalTrials.gov .